Neurochemistry

MPress Records Releases So Sure's Debut EP Caffeine Drip

Friday, July 10, 2020 - 9:05pm

NEW YORK, July 10, 2020 /PRNewswire-PRWeb/ -- MPress Records recording artists So Sure have released their debut EP Caffeine Drip, with 100% of the proceeds being donated to the ACLU to aid in their advocacy efforts to demand an end to racial injustice and police brutality.

Key Points: 
  • NEW YORK, July 10, 2020 /PRNewswire-PRWeb/ -- MPress Records recording artists So Sure have released their debut EP Caffeine Drip, with 100% of the proceeds being donated to the ACLU to aid in their advocacy efforts to demand an end to racial injustice and police brutality.
  • The full EP, available on all digital platforms and premiered by The Big Takeover , is the first offering from So Sure, which was officially formed during the Covid-19 pandemic.
  • The EP features songs that are all-too-timely and reflect the international frustration and anxiety due to the virus and recent protests sparked by the tragedy in Minneapolis.
  • So Sure's self-produced "Caffeine Drip" was recorded remotely between Savannah, GA, Montgomery, NY and Charleston, SC.

Saladax Biomedical launches clozapine test in the US after FDA grants market authorization

Wednesday, July 8, 2020 - 7:00pm

Saladax Biomedical Inc., announced that the FDA has granted their De Novo Request for a rapid blood test that measures clozapine levels in psychiatric patients.

Key Points: 
  • Saladax Biomedical Inc., announced that the FDA has granted their De Novo Request for a rapid blood test that measures clozapine levels in psychiatric patients.
  • This is a milestone in psychiatry as the MyCare Psychiatry Clozapine Assay Kit is the only commercial test available in the US for monitoring clozapine levels.
  • When used in conjunction with other laboratory and clinical information, this test can aid in the management of individuals prescribed clozapine for treatment resistant schizophrenia.
  • The availability of a fast and effective tool, like the Saladax Test, could be an important tool to improve the utilization of clozapine.

Xenon Lights Market Trajectory & Analytics to 2027 - COVID-19 Updated - ResearchAndMarkets.com

Tuesday, July 7, 2020 - 10:41am

The "Xenon Lights - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Xenon Lights - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Xenon Lights estimated at US$9.5 Billion in the year 2020, is projected to reach a revised size of US$20.6 Billion by 2027, growing at a CAGR of 11.7% over the analysis period 2020-2027.
  • This segment currently accounts for a 55.7% share of the global Xenon Lights market.
  • China, the world second largest economy, is forecast to reach an estimated market size of US$4.5 Billion in the year 2027 trailing a CAGR of 15.6% through 2027.

COVID-19 Panic Spikes Global Demand for Injectable Benzodiazepine: Future Market Insights Study

Monday, July 6, 2020 - 3:15pm

DUBAI, U.A.E, July 6, 2020 /PRNewswire/ -- Future Market Insight's projections reveal that the global injectable benzodiazepine market is set to shoot up significantly in 2020, reaching a value of US$ 260 Mn in the wake of the coronavirus pandemic.

Key Points: 
  • DUBAI, U.A.E, July 6, 2020 /PRNewswire/ -- Future Market Insight's projections reveal that the global injectable benzodiazepine market is set to shoot up significantly in 2020, reaching a value of US$ 260 Mn in the wake of the coronavirus pandemic.
  • Injectable benzodiazepine drugs are administered as the first course of treatment for bipolar disorders, dementia, schizophrenia, autism and anxiety disorders.
  • As a result of these increasing affliction cases, the demand for injectable benzodiazepine drugs is set to increase in the long-run.
  • For more insights into the Market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-11724
    Generic injectable benzodiazepine drugs are stealing the spotlight as they are more cost-effective.

COVID-19 Panic Spikes Global Demand for Injectable Benzodiazepine: Future Market Insights Study

Monday, July 6, 2020 - 3:15pm

DUBAI, U.A.E, July 6, 2020 /PRNewswire/ -- Future Market Insight's projections reveal that the global injectable benzodiazepine market is set to shoot up significantly in 2020, reaching a value of US$ 260 Mn in the wake of the coronavirus pandemic.

Key Points: 
  • DUBAI, U.A.E, July 6, 2020 /PRNewswire/ -- Future Market Insight's projections reveal that the global injectable benzodiazepine market is set to shoot up significantly in 2020, reaching a value of US$ 260 Mn in the wake of the coronavirus pandemic.
  • Injectable benzodiazepine drugs are administered as the first course of treatment for bipolar disorders, dementia, schizophrenia, autism and anxiety disorders.
  • As a result of these increasing affliction cases, the demand for injectable benzodiazepine drugs is set to increase in the long-run.
  • For more insights into the Market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-11724
    Generic injectable benzodiazepine drugs are stealing the spotlight as they are more cost-effective.

Eyenovia Resumes Recruitment of Phase III CHAPERONE Study for Progressive Myopia

Tuesday, June 30, 2020 - 9:05pm

We are excited to resume enrollment in our Phase III CHAPERONE study among nearly all of our clinical sites for the treatment of progressive myopia in children.

Key Points: 
  • We are excited to resume enrollment in our Phase III CHAPERONE study among nearly all of our clinical sites for the treatment of progressive myopia in children.
  • The CHAPERONE study is a U.S.-based, multi-center, randomized, double-masked trial that will enroll more than 400 children between 3-12 years of age.
  • The study is investigating the safety and efficacy of MicroPine for the reduction of progressive myopia using Eyenovias proprietary atropine topical micro-formulation delivered by the Optejet dispenser.
  • MicroPine (atropine ophthalmic solution) is Eyenovia's first-in-class topical treatment for progressive myopia, a back-of-the-eye condition commonly known as nearsightedness.

Bexson Biomedical Adds Industry Leaders Bill Carson And Noah Craft As Advisors

Tuesday, June 30, 2020 - 4:13pm

SANTA BARBARA, Calif., June 30, 2020 /PRNewswire/ -- Bexson Biomedical, Inc. announced today the addition of Bill Carson, MD and Noah Craft, MD, PhD as advisors to the company.

Key Points: 
  • SANTA BARBARA, Calif., June 30, 2020 /PRNewswire/ -- Bexson Biomedical, Inc. announced today the addition of Bill Carson, MD and Noah Craft, MD, PhD as advisors to the company.
  • These industry veterans bring valuable perspective to Bexson's R&D program and guidance for its novel ketamine delivery platform.
  • Carson and Crafts' experience and strategic vision on the Bexson team.
  • Dr. Carson's many FDA approvals and commercial success while leading Otsuka illustrate his ability to optimize technology in our highly regulated industry," said Gregg Peterson, Bexson CEO.

ECS Brands Acquires 10,000 Square Feet of R&D Facilities from Dean Foods to Facilitate Rapid Growth

Tuesday, June 23, 2020 - 10:00pm

BLOOMFIELD, Colo., June 23, 2020 /PRNewswire-PRWeb/ --With their rapid and continued growth, ECS Brands expands to commandeer former Dean Foods' 10,000 square foot research and development facility.

Key Points: 
  • BLOOMFIELD, Colo., June 23, 2020 /PRNewswire-PRWeb/ --With their rapid and continued growth, ECS Brands expands to commandeer former Dean Foods' 10,000 square foot research and development facility.
  • A group of leading and innovative visionaries, ECS Brands is poised to become a true disruptor of the ever-evolving hemp-based products market.
  • Along with the research and development lab space, ECS Brands will also acquire state-of-the-art equipment and a sensory testing facility.
  • ECS Brands is a forward thinking company with years of experience in plant-based science and endocannabinoid system (ECS) wellness initiatives.

Vicore Pharma Expands Recruitment Base for the ATTRACT study

Tuesday, June 23, 2020 - 7:11am

In order to accelerate recruitment in the ATTRACT study, Vicore Pharma has performed a thorough review to assess feasibility in countries outside UK and has filed a clinical trial application in India that was approved in record time.

Key Points: 
  • In order to accelerate recruitment in the ATTRACT study, Vicore Pharma has performed a thorough review to assess feasibility in countries outside UK and has filed a clinical trial application in India that was approved in record time.
  • Adding clinical sites in India will contribute to accelerate enrolment in the ATTRACT study".
  • The study, named ATTRACT (Angiotensin II Type Two Receptor Agonist COVID-19 Trial), is targeting hospitalized patients treated with basic respiratory care, and not yet on mechanical ventilation.
  • In addition, Vicore Pharma has recently announced the award of a 1.5 million grant from the UK-based self-funded medical research charity LifeArc to part-fund the study.

YOUTH EXPOSED HUNDREDS OF MILLIONS OF TIMES TO NONCOMPLIANT ALCOHOL ADS ON CABLE TV

Friday, June 19, 2020 - 2:00pm

With support from the Centers for Disease Control and Prevention (CDC), the Abt/Boston University team is monitoring total and noncompliant youth exposure to alcohol ads on cable TV.

Key Points: 
  • With support from the Centers for Disease Control and Prevention (CDC), the Abt/Boston University team is monitoring total and noncompliant youth exposure to alcohol ads on cable TV.
  • The study found that:
    Total youth exposure to alcohol ads on cable TV decreased by 16 percent, and noncompliant exposure decreased by 26 percent.
  • The 25 alcohol brands with the most noncompliant alcohol ad exposure were responsible for 71 percent of all noncompliant ads.
  • By monitoring alcohol ads on cable TV, we can help hold the alcohol industry accountable to its guidelines designed to prevent adolescent alcohol use.